News from the Greater Intermountain Node: Upcoming Cannabis Seminar and CTN-0151 Updates

Greater Intermountain Node Seminar Series “On the Rocks”

On the Rocks (OTR) is the Greater Intermountain Node’s (GIN) monthly Research Discussion Series, spotlighting standout addiction-related research from across the Greater Intermountain community. Designed for dynamic exchange, OTR fosters collaboration and fresh thinking through interactive conversations between presenters and attendees. The series name nods to the stunning Rocky Mountain backdrop and the iconic Utah trails just steps from our offices.

Join us for the next OTR on Wednesday, October 1, 2025, from 12–1 PM MST, featuring “Cannabis: Balancing Risk and Therapeutic Potential” with Marcel O. Bonn-Miller, PhD.

Dr. Bonn-Miller will share insights from three key research areas: Cannabis Use Disorder, the therapeutic promise of cannabinoids, and regulatory science. He’ll present findings on cannabis use among veterans with PTSD, explore cannabinoid-based treatments for sleep, anxiety, and substance use disorders, and discuss CBD safety standards and regulatory frameworks.

Dr. Bonn-Miller holds a BA and PhD in clinical psychology from the University of Vermont and completed a postdoctoral fellowship at Stanford. He launched his research career at the VA and University of Pennsylvania, later leading cannabis research in both academic and industry settings. He now serves as Chief Scientific Officer at Charlotte’s Web and has authored over 175 peer-reviewed publications.

Visit the OTR website to learn how to join. Free CME/CE credit available for live attendees.

CTN-0151 Update

The Greater Intermountain Node is proud to collaborate with the University of Tennessee Health Science Center, Dr. Kenneth Hohmeier, and Dr. Rachel Barenie on CTN-0151: Toward Pharmacy-Led Value Based Care Model for Buprenorphine Initiation and Management (PharmValue). This multi-method research initiative explores how community pharmacists can play a greater role in managing opioid use disorder (OUD) treatment, specifically through buprenorphine prescribing and management.

With treatment demand exceeding current capacity nationwide, this study aims to develop a scalable, pharmacist-led collaborative care model to improve access to medication for OUD (MOUD). The project includes stakeholder interviews, a national survey of pharmacy law experts, and a comprehensive 50-state legal and regulatory review. These efforts will inform the creation of a model Collaborative Pharmacy Practice Agreement (CPPA), enabling pharmacists to initiate and manage buprenorphine treatment in retail pharmacy settings. By leveraging pharmacist accessibility and trust within communities, this model has the potential to transform MOUD care delivery across the U.S.

Posted on September 16, 2025.